Forward Pharma Reports Fourth Quarter and Year End 2014

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Forward Pharma Reports Fourth Quarter and Year End 2014 Financial and Operational Results

COPENHAGEN, Denmark, March 25, 2015 (GLOBE NEWSWIRE) -- Forward Pharma A/S (Nasdaq: FWP ), today reported financial results for the fourth quarter and year ended December 31, 2014. Net loss for the fourth quarter and year ended December 31, 2014 was $2.0 million and $19.0 million, respectively. Loss per share for the fourth quarter and year ended December 31, 2014 was $1.01 and $1.79, respectively, after accounting for a non-cash preferential distribution of approximately $42.7 million. As of December 31, 2014, Forward had $223.5 million in cash, cash equivalents and marketable securities, with no debt outstanding.

"We expect 2015 to be an eventful year for Forward," said Peder Andersen, Chief Executive Officer of Forward. "After successfully raising approximately $215 million in net proceeds from our IPO in October 2014, the Company's top priorities are to continue to advance our lead drug candidate FP187 while we exploit and defend our intellectual property rights."

Fourth Quarter and Year End 2014 Financial and Operational Results

The net loss for the fourth quarter of 2014 was $2.0 million compared to a net loss of $11.0 million for the fourth quarter of 2013, as 4Q14 benefited from a $5.6 million net exchange rate gain while 4Q13 included a $8.8 million expense in connection with the fair value adjustment for shareholder warrants. The net loss for 2014 was $19.0 million compared to a net loss of $15.7 million in 2013.

Research and development expenses were $3.9 million for the fourth quarter ended December 31, 2014, compared to $1.7 million for the same period in 2013. The increase in research and development expenses was due primarily to increased FP187 patent-related costs as well as share-based compensation expense. Research and development costs for each of the years ended December 31, 2014 and 2013 were $10.5 million and $8.0 million, respectively. The $2.5 million increase in 2014 was primarily due to patent-related expenses for FP187, which increased to $4.7 million in 2014 from $1.5 million in 2013. In addition, share-based compensation expense increased to $1.8 million in 2014 compared to $579,000 in 2013. Offsetting these increases was a reduction in the use of external vendors to support our clinical development activities conducted in 2014, resulting in decreased research and development costs of $2.0 million. We expect research and development costs to increase in 2015 as we advance the clinical development of FP187 with initiation of a Phase 3 trial within the next 12 months.

General and administrative expenses were $4.0 million for the fourth quarter of 2014 versus $0.4 million for the fourth quarter of 2013. The increase in general and administrative expenses was primarily due to increased share-based compensation expense of $2.5 million and general and administrative expenses related to our becoming a public company in 2014. General and administrative expenses were approximately $9.2 million for 2014 versus $1.0 million for 2013. The $8.2 million increase in 2014 resulted primarily from costs related to the preparation for our IPO in the amount of $2.0 million as well as an increase in share-based compensation expense of $4.2 million. The remaining increase is attributable to increased personnel costs and office costs related to the opening of our U.S. subsidiary in 2014. We expect that our general and administrative costs will increase in 2015 as we expand our business, defend our intellectual property, and incur additional costs associated with operating as a public company.

Non-cash stock-based compensation expense included in total operating expenses was $2.5 million for the fourth quarter of 2014 versus $0.2 million for the fourth quarter of 2013. Non-cash stock-based compensation expense included in total operating expenses was $6.0 million for 2014 versus $579,000 million for 2013. The increase in stock-based compensation expense was due to increased hiring of key personnel in 2014.

As of December 31, 2014 and 2013, Forward had $223.5 million and $3.0 million in cash, cash equivalents and marketable securities, respectively. The net increase of $220.5 million in cash, cash equivalents and marketable securities during 2014 is primarily due to the Company's 2014 IPO.

Recent IP progress and outlook

In 2014, we made significant progress in advancing our intellectual property portfolio. The following summarizes the current status of several of our most important U.S. and European patents and patent applications.

  • We are awaiting further action by the USPTO regarding our U.S. patent application No. 11/576,871. A USPTO examiner previously found our claims in this application directed to methods of treating MS using a daily 480 mg dose of DMF to be allowable and has recommended that an interference be declared against Biogen's U.S. patent No. 8,399,514.
  • We have two pending U.S. patent applications relating to the 480 mg dose of DMF that we believe may soon be allowed, one of which (14/213,399) claims particular up-titration schedules of using DMF to treat MS, and the other of which (14/212,503) claims treating MS using particular compositions containing DMF and that also specifies levels of a DMF metabolite called mono methyl fumarate (MMF) in the bloodstream.
  • Our erosion matrix patent issued on December 9, 2014 with patent number 8,906,420. This patent expires in January 2030 and covers the formulation of FP187.
  • On November 18, 2014, we filed a lawsuit against Biogen alleging infringement of our German utility model. An oral proceeding in Germany is scheduled for February 16, 2016.

Clinical progress and outlook

Our development plan for our lead drug, FP187, includes preparation for a Phase 3 program in multiple sclerosis, psoriasis or both, as well as other clinical programs. Forward anticipates the following development activities related to clinical trials for FP187:

  • continue to pursue development of FP187 for the treatment of MS and/or psoriasis and commence a Phase 3 trial within the next 12 months;
  • initiate a Phase 1 bridging study to investigate the pharmacokinetic profile of a new tablet formulation of FP187; and
  • initiate a Phase 1 fed/fast pharmacokinetic trial in 2Q15 which is a regulatory requirement for controlled release drugs.

About Forward Pharma:

Forward Pharma A/S is a Danish biopharmaceutical company (the "Company or "Forward Pharma") developing FP187, a proprietary formulation of DMF (dimethyl fumarate) for the treatment of inflammatory and neurological indications. Since our founding in 2005, we have worked to advance unique formulations of DMF, an immune modulator, as a therapeutic to improve the health and well-being of patients with immune disorders including multiple sclerosis. FP187, our clinical candidate, is a DMF formulation in a delayed and slow release oral dose.

Our principal executive offices are located at Østergade 24A, 1, 1100 Copenhagen K, Denmark and our American Depositary Shares are publicly traded on NASDAQ Stock Market (symbol: FWP). For more information about the Company's products and developments, please visit our web site at www.forward-pharma.com

         
Forward Pharma A/S
Condensed Consolidated Statement of Operations
(in thousands, expect per share amounts)
         
   Year Ended   Three Months Ended 
   December 31st   December 31st 
  2014 2013 2014 2013
         
Research and development  $ (10,547)  $ (8,018)  $ (3,931)  $ (1,704)
General and adminstrative  (9,154)  (1,014)  (3,998)  (387)
Total operating expenses (1)  (19,701)  (9,032)  (7,929)  (2,091)
         
Fair value adjustments  (4,791)  (6,676)  84  (8,802)
Foreign exchange gain  5,589  --   5,589  -- 
Other  (113)  12  285  (89)
Net (loss)  (19,016)  (15,696)  (1,971)  (10,982)
         
Preferential distribution  (42,734)  --   (42,734)  -- 
Net (loss) used to compute per share amounts  $ (61,750)  $ (15,696)  $ (44,705)  $ (10,982)
         
Net (loss) per ordinary share        
Basic and diluted (2)  $ (1.79)  $ (0.54)  $ (1.01)  $ (0.38)
         
Weighted-average shares        
Basic and diluted  34,490  29,004  44,094  29,089
         
(1) Operating expenses include share based compensation: $6.0 million and $2.5 million for 2014 and 4Q14, respectively, versus $579,000 and $220,000 for 2013 and 4Q13, respectively.
(2) The net loss used to compute the per share amounts for the year and quarter ended December 31, 2014 has been increased by a non-cash preferential distribution of approximately $42.7 million.
         
         
Forward Pharma A/S    
Condensed Consolidated Statement of Operations    
(in thousands)    
         
   December 31,     
  2014 2013    
Assets        
Cash, cash equivalents and marketable securities  $ 223,484  $ 2,955    
Other assets  1,825  644    
Total assets  $ 225,309  $ 3,599    
         
Equity and Liabilities        
Shareholder equity (deficit)  $ 222,394  $ (26,415)    
Liabilities  2,915  30,014    
Total equity and liabilities  $ 225,309  $ 3,599    

Forward Pharma A/S Media Contact:
Sharon Klahre, Director, Investor Relations
Forward Pharma USA, LLC
7 Skyline Drive
Hawthorne, NY 10532
SK@forward-pharma.com
+1 914-752-3542

The Ruth Group
Lee Roth
lroth@theruthgroup.com
+1 646-536-7014

Forward Looking Statements:

Certain statements in this press release may constitute "forward-looking statements" of the Company within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements which contain language such as "believe,""expect," "hope," "would" and "potential." Forward-looking statements are predictions only which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those expressed in such statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: the Company's ability to obtain, maintain and defend issued patents with protective claims; the commencement of any patent interference or infringement action; the Company's ability to prevail in or obtain a favorable decision in any such action; the Company's ability to recover damages in any such action; uncertainties relating to our development plans and activities, including the results, timing, cost and location thereof; risks and uncertainties related to the scope, validity and enforceability of our intellectual property rights in general and the impact on us of patents and other intellectual property right of third parties. These and other factors are identified and described in detail in certain of our filings with the United States Securities and Exchange Commission, including our Annual Report on Form 20-F for the year ended December 31, 2014.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

S&P Global's UBS AI Conference Slot Deserves Attention

Updated Category News Views 109

Thirty Minutes Can Still Matter A half-hour fireside chat is not a quarterly earnings call, and anybody treating it like one is setting themselves up for disappointment. Still, S&P Global CEO Martina Cheung appearing at the UBS Global Technology and AI Conference on December 2 deserves a spot on the calendar for owners of NYSE:SPGI. This is a company sitting in the middle...

Continue Reading
Payoneer Gets OCC Nod, but the Finish Line Is Ahead

Updated Category News Views 121

Federal bank paperwork is not usually thrilling, yet Payoneer just found a potentially meaningful lever for its cross-border payments machine. The company received preliminary conditional approval from the Office of the Comptroller of the Currency to form PAYO Digital Bank, a national trust bank intended to support stablecoin services. That is a real regulatory milestone...

Continue Reading
Nevada’s Space Academy Bid Has Assets, Not a Win Yet

Updated Category News Views 29

Desert acreage and a moon-landing backstory make for a handsome pitch, but Nevada is still standing at the starting line. The state has submitted its official response to NASA’s Request for Information for a proposed United States Space Academy, and the new promotional video is meant to show why the Silver State belongs in the conversation. Fair enough. There is real...

Continue Reading
Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 91

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 69

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 116

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading
Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 83

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
AMD Faces Fresh Scrutiny Over China Supply Exposure

Updated Category News Views 130

One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...

Continue Reading
KidneyVoter Push Turns Patient Frustration Into Clout

Updated Category News Views 313

A ballot registration drive rarely tells the whole story, but it can reveal where the pressure is building. The American Association of Kidney Patients says its 2026 nonpartisan KidneyVoter™ effort, “50 States in 50 Days,” reached constituencies in every state after launching September 14. That does not produce a clean vote total or prove legislators will suddenly...

Continue Reading
Pinnacol’s Community Work Earns Denver Chamber Recognition

Updated Category News Views 67

A workers’ comp insurer usually becomes visible on somebody’s worst day; Pinnacol Assurance is being recognized for the work it keeps doing around those days. The Denver Metro Chamber of Commerce has given the Colorado-based, member-owned carrier its 2026 Business Impact Award for Corporate Social Responsibility. Awards can be cheap applause, frankly. This one...

Continue Reading

Top 5 Most Recently Viewed Articles

Transforming Lives with Sober.Buzz: Embrace the $BUZZ Journey

Updated Category News Views 568

Welcome to Sober.Buzz and the Journey of Transformation Sober.Buzz introduces the Sober Token, known for its symbol $BUZZ, representing a promising initiative aimed at creating a supportive and empowering global community for individuals in recovery from addiction. Designed by those who understand the struggles, the project offers hope and encouragement for those seeking...

Continue Reading
Revolutionizing Ecommerce with Artifi's AI Product Setup Tool

Updated Category News Views 188

Introduction to Artifi's New AI Feature Artifi, a dynamic player in SaaS solutions for product customization, has announced a groundbreaking new feature known as AI Automated Product Setup. This innovative tool aims to drastically reduce setup times, allowing suppliers to efficiently prepare their product data for ecommerce platforms. Understanding the Setup Process The...

Continue Reading
Cleeng Pro: Revolutionizing D2C Subscription Management Today

Updated Category News Views 180

Cleeng Pro: An Innovative Platform for D2C Subscriptions Cleeng, a leader in Subscriber Retention Management, has recently introduced Cleeng Pro, a groundbreaking direct-to-consumer (D2C) subscription platform. This platform empowers creators, developers, and entrepreneurs to establish their subscription services with remarkable efficiency, all without any cost for their...

Continue Reading
SciBase's Nevisense Device Sold to NIH: A New Era in Dermatology

Updated Category News Views 255

SciBase Holding AB hit the headlines back in 2024 when it announced the sale of its flagship device, Nevisense, to the National Institutes of Health (NIH). Traders were buzzing, not just because SciBase is known for its cutting-edge dermatology tech, but because this sale signaled a massive leap into uncharted territory regarding skin health. The NIH isn't just any buyer;...

Continue Reading
FLUENT Launches Innovative MOODS Black in the Sunshine State

Updated Category News Views 262

FLUENT Launches Innovative MOODS Black in the Sunshine State FLUENT Corp. (CSE: FNT.U) (OTCQB: CNTMF), a leading national cannabis company, is thrilled to announce the exciting launch of its latest product, MOODS Black. This new addition to the well-regarded MOODS lineup showcases high-potency cannabis oil infused with cannabis-derived terpenes, ensuring a superior and...

Continue Reading